Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA
DOI:
https://doi.org/10.2340/16501977-2651Keywords:
incobotulinumtoxinA, botulinum neurotoxin type A, shoulder spasticity, upper-limb, lower-limb, stroke.Abstract
Objective: The Titration study in lOWer and uppER-limb spasticity (TOWER) study (NCT01603459), evaluated incobotulinumtoxinA for upper- and lower-limb spasticity. This post hoc analysis assessed shoulder spasticity in patients who received injections into the shoulder. Methods: Subjects received 3 injection cycles with escalating incobotulinumtoxinA doses on the same side (400, 600, 600?800 U; ??600 U per limb including optional shoulder dose, planned range 100?250 U). Joint function was assessed with the Ashworth Scale shoulder sumscore (AS-SSS) in subjects treated in the shoulder vs those who were not. Safety was assessed in subjects treated in the shoulder, and in those who had upper-limb treatment without shoulder treatment. Results: The proportion of subjects receiving shoulder treatment increased with escalating dose at each cycle (n?=?84/140 (60.0%) by cycle 3; mean (standard deviation (SD)) shoulder dose 118.4 U (SD 60.2)). From baseline to 4-weeks post-injection, mean AS-SSS improved by ?1.1 (SD 1.9), ?1.7 (SD 1.8) and ?1.7 (1.8) in cycles 1, 2 and 3, respectively, in subjects treated in the shoulder, and ?0.5 (SD 1.3), ?0.8 (SD 1.6) and ?0.9 (SD 1.4) in subjects who were not. A significant dose effect on AS-SSS was observed in cycle 3 (p?=?0.0081). No unexpected safety concerns were reported. Conclusion: The results demonstrate an improvement in shoulder spasticity and safety following incobotulinumtoxinA treatment.Downloads
Downloads
Published
How to Cite
Issue
Section
License
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.


